Фундаментальные и клинические исследования в онкологии. Существуют ли предпосылки для прорыва?
https://doi.org/10.17650/1818-8346-2014-9-4-54-66
Аннотация
Появление противоопухолевых препаратов совершило революцию в лечении злокачественных новообразований, позволив добиться излечения пациентов с рядом ранее фатальных заболеваний или продления жизни у больных с неизлечимыми опухолями. В настоящее время зарегистрировано уже более 100 противоопухолевых препаратов, многие из которых разработаны в последние годы с использованием самых современных достижений в области молекулярной биологии опухолей. Одновременно цена новых противоопухолевых препаратов растет темпами, значимо опережающими увеличение эффективности противоопухолевой терапии. Подобная ситуация наблюдается во многом из-за того, что сложившаяся система внедрения новых противоопухолевых препаратов не выполняет исходно возложенных на нее задач.
Об авторах
Н. В. Жуков
ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России, Москва; 117997, Россия, Москва, ул. Островитянова, 1
ФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России, Москва; 117198, Россия, Москва, ул. Саморы Машела, 1
Россия
Россия
С. А. Румянцев
ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России, Москва; 117997, Россия, Москва, ул. Островитянова, 1
ФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева Минздрава России, Москва; 117198, Россия, Москва, ул. Саморы Машела, 1
Россия
Россия
С. А. Лукьянов
ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России, Москва; 117997, Россия, Москва, ул. Островитянова, 1
ФГБУН ИБХ имени академиков М.М. Шемякина и Ю.А. Овчинникова РАН, Москва; 117997, Россия, ГСП-7, Москва, улица Миклухо-Маклая, 16/10
Россия
Россия
Список литературы
1. Burris H.A.R., Moore M.J., Andersen J. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403–13.
2. Moore M.J., Goldstein D., Hamm J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25: 1960–6.
3. Saltz L., Clarke S., Diaz-Rubio E. et al. Bevacizumab (bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Proc Am Soc Clin Oncol 2007;25:170s. Abstr. 4028.
4. Van Cutsem E., Nowacki M., Lang I. et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Proc Am Soc Clin Oncol 2007;25:164s. Abstr. 4000.
5. Miles D., Chan A., Romieu G. et al. Final overall survival (OS) results from the randomised, double-blind, placebocontrolled, phase III AVADO study of bevacizumab (BV) plus docetaxel (D) compared with placebo (PL) plus D for the firstline treatment of locally recurrent (LR) or metastatic breast cancer (MBC). Cancer Research Suppl 2009;69(24):abstr. 41.
6. Cortes J., O’Shaughnessy J., Loesch D. et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914–23.
7. Cameron D., Casey M., Oliva C. et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010;15:924–34.
8. Smith I., Procter M., Gelber R.D. et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29–36.
9. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74.
10. Chen Y., Wang H., Kantarjian H., Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma 2013;54(7):1411–7.
11. Rugo H.S. Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning? J Clin Oncol 2012;30(9):898–901.
12. Teicher B.A. Tumor models for efficacy determination. Mol Cancer Ther 2006;5(10):2435–43.
13. Silverman E. Clinical Trial Costs Are Rising Rapidly. PharmaBlog 2011. URL: http://www.pharmalot.com/2011/07/clinical-trial-costs-for-each-patient-roserapidly/.
14. Balduzzi A., Valsecchi M.G., Uderzo C. et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005;366(9486):635–42.
15. Hortobagyi G.N. Optimal Therapy for Primary and Metastatic Breast Cancer: Emerging Standards and New Approaches. San Antonio, Texas, December 13, 2001. URL: http://www.medscape.org/viewprogram/1021.
16. Cuzick J., Sestak I., Baum M. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncology 2010;11(12):1135–41.
17. Joerger M., Thürlimann B. Update of the BIG 1-98 Trial: where do we stand? Breast 2009;18(Suppl 3):S78–82.
18. Buzdar A., Hunt K., Buchholz T.A. et al. Improving survival of patients with breast cancer over the past 6 decades: The University of Texas M.D. Anderson Cancer Center experience. Breast Cancer Symposium, 2010. Abstr. 176. URL: http://www.asco.org/ascov2/Meetings/Abstrracts?vmview=abstr_detail_view&confID=100&abstrractID=60172.
19. Vasella D., Slater R. Magic Cancer Bullet: How a Tiny Orange Pill is Rewriting Medical History. New York: HarperBusiness, 2003.
20. Gambacorti-Passerini C., Antolini L., Mahon F.X. et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103(7):553–61.
21. Heng D.Y., Xie W., Regan M. et al. A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials. GUCS2012; abstr. 353.
22. Stewart D.J., Kurzrock R. Cancer: The Road to Amiens. J Clin Oncol 2009;27(3):328–33.
23. Humphreys K., Trafton J., Wagner T.H. The cost of institutional review board procedures in multicenter observational research. Ann Intern Med 2003;139:77.
24. Koski G. Research ethics and oversight: Revolution, or just going around in circles? The Monitor 2007;21:55–7.
25. Schutz F.A., Je Y., Richards C.J., Choueiri T.K. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012;30(8):871–7.
26. Ranpura V., Hapani S., Wu S. Treatmentrelated mortality with bevacizumab in cancer patients. JAMA 2011;305;487–94.
27. Amir E., Seruga B., Niraula S. et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011;103(17): 1299–309.
28. Ladewski L.A., Belknap S.M, Nebeker J.R. et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 2003;21(20):3859–66.
29. URL: http://www.medicines.org.uk/EMC/Default.aspx.
30. URL: http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional.
31. URL: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
32. Aebi S., Davidson T., Gruber G. et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 (suppl 6):vi12–vi24.
33. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. The Adjuvant Breast Cancer Trials Collaborative Group. J Natl Cancer Inst 2007;99(7):516–25.
34. Hackshaw A., Baum M., Fornander T. et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 2009;101:341–9.
35. Robert N.J., Wang M., Cella D. et al. Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary nodenegative receptor-positive breast cancer < 3 cm. Proc Am Soc Clin Oncol 2003;22:5 (abstr. 16).
36. Schiffer C.A. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol 2003;21:760–1.
Рецензия
Для цитирования:
Жуков Н.В., Румянцев С.А., Лукьянов С.А. Фундаментальные и клинические исследования в онкологии. Существуют ли предпосылки для прорыва? Онкогематология. 2014;9(4):54-66. https://doi.org/10.17650/1818-8346-2014-9-4-54-66
For citation:
Zhukov N.V., Rumyantsev S.A., Lukyanov S.A. Basic and clinical research in oncology: is there background for a breakthrough? Oncohematology. 2014;9(4):54-66. (In Russ.) https://doi.org/10.17650/1818-8346-2014-9-4-54-66
Просмотров:
9941
Послать статью по эл. почте 